Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.67 | 1.36 |
NAV | ₹103.08 | ₹199.50 |
Fund Started | 09 Nov 2007 | 07 May 2007 |
Fund Size | ₹11731.01 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1%, if redeemed within 90 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 1.85% | 4.60% |
3 Year | 24.98% | 26.42% |
5 Year | 29.33% | 29.95% |
1 Year
3 Year
5 Year
Equity | 96.40% | 93.60% |
Cash | 0.23% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Max Healthcare Institute Ltd. | 3.07% |
Coforge Ltd. | 2.68% |
Persistent Systems Ltd. | 2.42% |
Fortis Healthcare Ltd. | 2.37% |
PB Fintech Ltd. | 2.26% |
UNO Minda Ltd. | 2.19% |
Indian Bank | 2.15% |
Solar Industries India Ltd. | 2.05% |
Dixon Technologies (India) Ltd. | 2.04% |
CG Power and Industrial Solutions Ltd. | 2.03% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Sahil Shah | Chirag Setalvad |
Start Date | 14 Feb 2024 | 28 Jun 2014 |
Name
Start Date
Description | The scheme aims to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of Mid Cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 09 Nov 2007 | 07 May 2007 |
Description
Launch Date